Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

- PMLiVE

CHMP thumbs up for Novo’s obesity drug Saxenda

Diabetes drug liraglutide on course for new indication in EU

- PMLiVE

Novo Nordisk’s Xultophy debuts in Switzerland

It is the first market for combination of diabetes treatments Tresiba and Victoza

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

Novo launches community health programme in New Jersey

Designed to support healthy lifestyle

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

Novo’s ‘virtual mannequins’ win digital award at PMEA

Med ed programme Decisions in Time was delivered with emotive

- PMLiVE

Diabetes puts economic growth at risk, says IDF

Comments come on World Diabetes Day

- PMLiVE

The rising prevalence of diabetes in Europe

The condition is still an unstoppable epidemic

- PMLiVE

Servier licenses device that could ‘reshape’ diabetes care

Tiny pump implant to deliver GLP-1 agonist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links